World Number Two tennis player Iga Swiatek's positive test for a little-known product called Trimetazidine raises the issue of whether drug testing is going too far. Should there not be a threshold for the level of prohibited substances found in the body? Is there a performance advantage? What fault lies with the athlete? No matter the final outcome, an athlete remains tainted no matter their potential innocence, which could affect performance and sponsorship agreements. In this Spotlight episode, the team discuss the case, its similarities and differences compared to tennis' other high profile doping case, Janik Sinner, and what it means for anti-doping.SHOW NOTES:Join DiscourseIf you fancy a bit of the coaching, sports science and sports news conversations with our amazing members, consider a small donation to become a Patron of the site, and get access to our Discourse community, where you can join like-minded fans and sports enthusiasts to keep the conversation going.The ITA decision statementBBC story on Swiatek's one-month banSwiatek's statement on InstagramThe timeline of Swiatek's doping caseResponse from the manufacturer of the drugArticle on Jack Burke's KOMsWhen Burke broke the Alp d'Huez KOMJack Burke's Strava account Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related